#United States #Class Action #San Francisco #Hagens Berman #PROCEPT BioRobotics

Urgent Alert for PROCEPT BioRobotics Investors

Investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) should take immediate notice of an ongoing securities class action that could have significant implications for their investments. The law firm Hagens Berman Sobol Shapiro LLP has issued a warning, highlighting the critical date of September 22, 2026, which marks the lead plaintiff deadline in this case. This is particularly important for those who acquired shares in PROCEPT between February 28, 2024, and February 25, 2026.

Overview of the Class Action Lawsuit

The class action lawsuit stems from allegations that the company engaged in deceptive sales practices regarding its single-use handpiece used in the Aquablation therapy, a procedure aimed at treating patients with enlarged prostates. Investors are reportedly frustrated due to a series of disappointing quarterly sales results combined with sudden announcements about excess inventory levels that were hidden from public view.

The main focus of the lawsuit is whether PROCEPT and other defendants in the case misled investors concerning sales numbers and overall financial health. In particular, the complaint outlines how the company was engaging in an extensive discount program that incentivized bulk orders, which led to inflated sales figures that did not reflect actual demand from customers.

Timeline of Events

The company’s decline in credibility became evident through multiple disclosures that revealed a concerning trend in sales. On August 6, 2025, PROCEPT's quarterly report revealed a significant underperformance in handpiece sales, catching many investors off-guard as it fell well below consensus expectations. This trend continued with the company's Q3 results, where they further reduced annual sales guidance amid concerns about managing customer inventory effectively. Notably, management admitted that some of their clients were holding onto significantly more units than necessary.

The situation deteriorated further on February 25, 2026, when PROCEPT acknowledged that handpiece sales had regularly outstripped actual procedures conducted at U.S. sites since early 2023. This revelation indicated that over 10,000 units remained unsold in customer inventories, a situation made worse by the company's decision to maintain obscure discounts that only exacerbated future sales issues.

As news broke, the company's stock price plummeted more than 48%, falling by $22.06 since early August 2025, raising alarms about transparency and accountability. Reed Kathrein, a partner at Hagens Berman, indicated the firm’s focus is on assessing whether the company intentionally inflated sales figures and whether it adequately communicated with investors about its true financial condition.

Importance of Acting by the Deadline

For investors who may have faced substantial losses due to insufficient disclosures, it is vital to act swiftly. Those who think they meet eligibility requirements are strongly encouraged to gather their documentation regarding their investments and to contact Hagens Berman for potential involvement in the lawsuit.

In addition to the legal ramifications, the firm provides an opportunity for whistleblowers holding non-public information about the company to come forward, potentially receiving a reward under the SEC Whistleblower program.

Conclusion

As the deadline approaches, it is imperative for investors in PROCEPT BioRobotics to understand their rights and take necessary actions. The next few months will be crucial as the firm prepares to move forward with the case. Readers looking to get involved or find more information can reach out via their official channels or by visiting the Hagens Berman website. For those who believe they hold relevant information or can provide insight into the investigation, this is an opportune moment to contribute.

For additional updates, feel free to follow Hagens Berman across social media on platforms like Twitter. Don’t wait until it’s too late—understanding your investment landscape is essential for making informed decisions going forward.